Skip To Main Content
Tzu-Yin Chen on Muck Rack

Tzu-Yin Chen

As seen in: Nature, Wiley Online Library, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tzu-Yin

Contact Tzu-Yin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Poly-β-D-(1,6)-N-acetyl-glucosamine (PNAG) glycan vaccines with broad spectrum neutralizing activities - Nature Communications

|
By Tzu-Yin Chen, Philip Harris, Jiun-Jie Shie
| Nature Verified
Abstract The development of bacterial vaccines is a complex challenge due to the substantial serological diversity of protective antigens. One promising antigenic target is the conserved surface polysaccharide poly-β-(1,6)-N-acetyl-D-glucosamine (PNAG). Despite its widespread distribution, antibodies raised against PNAG have shown restricted efficacy in promoting microbial elimination in vitro and safeguarding against infections in vivo.
Open in Who Shared Issue with article?

Effect of Sulfotyrosine and Negatively Charged Amino Acid of Leech‐Derived Peptides on Binding and Inhibitory Activity Against Thrombin

|
By Tzu-Yin Chen, Lakshmi C. Wijeyewickrema, Eileen Shyur, Tzu-Hsuan Ma
| Wiley Online Library Verified
Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Open in Who Shared View Duplicates (418) Issue with article?

Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies

|
By Chien-Tzu Huang, Tzu-Yin Chen, Yi-Chang Liu, Ching-Ping Lee
| MDPI
1. Introduction Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged as an ongoing global pandemic in 2020. As of 20 March 2023, a total of 10,236,886 confirmed cases with 18,803 deaths have been reported by the Taiwan Centers for Disease Control. In Taiwan, more than 90% of COVID-19-related deaths have occurred among patients with comorbidities [1].
Open in Who Shared Issue with article?
See all 4 articles